XML 162 R132.htm IDEA: XBRL DOCUMENT v3.24.0.1
Segment, Geographic and Other Revenue Information - Narrative (Detail)
treatmentCourse in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
USD ($)
country
treatmentCourse
operatingSegment
Dec. 31, 2022
USD ($)
country
Dec. 31, 2021
country
Segment Reporting Information [Line Items]      
Number of operating segments | operatingSegment 2    
Total assets $ 226,501.0 $ 197,205.0  
Deferred revenues, current 2,700.0 2,520.0  
Comirnaty [Member]      
Segment Reporting Information [Line Items]      
Remaining performance obligation 6,000.0    
Paxlovid [Member]      
Segment Reporting Information [Line Items]      
Remaining performance obligation $ 3,400.0    
Paxlovid, EUA-Labeled [Member]      
Segment Reporting Information [Line Items]      
Estimated government emergency use authorization inventory to be returned to company, number of treatment courses | treatmentCourse 6.5    
Reversal of revenue $ 3,500.0    
Paxlovid, NDA-Labeled, Commercial Supply [Member]      
Segment Reporting Information [Line Items]      
Supply commitment, minimum amount committed, number of treatment courses | treatmentCourse 6.5    
Paxlovid, NDA-Labeled, U.S. Strategic National Stockpile [Member]      
Segment Reporting Information [Line Items]      
Supply commitment, minimum amount committed, number of treatment courses | treatmentCourse 1.0    
Paxlovid, NDA-Labeled [Member]      
Segment Reporting Information [Line Items]      
Supply commitment, minimum amount committed, number of treatment courses | treatmentCourse 7.5    
Government and Government Sponsored [Member] | Comirnaty [Member]      
Segment Reporting Information [Line Items]      
Deferred revenues $ 1,700.0 2,500.0  
Deferred revenues, current 1,100.0 2,400.0  
Deferred revenues, noncurrent 552.0 $ 77.0  
Deferred revenue, revenue recognized 2,200.0    
Government and Government Sponsored [Member] | Paxlovid [Member]      
Segment Reporting Information [Line Items]      
Deferred revenues 3,400.0    
Deferred revenues, current 1,500.0    
Deferred revenues, noncurrent $ 1,900.0    
Geographic Concentration Risk [Member] | Revenue [Member] | Outside United States [Member]      
Segment Reporting Information [Line Items]      
Number of countries with revenue exceeding $500 million | country 14 24 21
Geographic Concentration Risk [Member] | Revenue [Member] | U.S. [Member]      
Segment Reporting Information [Line Items]      
Concentration risk, percentage 10.00% 10.00% 10.00%
Geographic Concentration Risk [Member] | Revenue [Member] | Japan [Member]      
Segment Reporting Information [Line Items]      
Concentration risk, percentage 6.00% 8.00% 9.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Largest U.S. Wholesaler Customers [Member]      
Segment Reporting Information [Line Items]      
Concentration risk, percentage 44.00% 32.00%